首页 正文

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Jan:157:114087. doi: 10.1016/j.biopha.2022.114087 Q17.52025

Kaempferol attenuates doxorubicin-induced renal tubular injury by inhibiting ROS/ASK1-mediated activation of the MAPK signaling pathway

黄酮通过抑制ROS/ASK1介导的MAPK信号通路激活来减轻柔红霉素诱导的肾小管损伤 翻译改进

Qijing Wu  1, Juan Chen  1, Xiyin Zheng  1, Jing Song  1, Lulu Yin  1, Hai Guo  1, Qian Chen  1, Yi Liu  1, Qianli Ma  1, Hong Zhang  2, Qianqian Yang  3

作者单位 +展开

作者单位

  • 1 The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu Province, China.
  • 2 The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu Province, China. Electronic address: zhh79318@163.com.
  • 3 The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu Province, China. Electronic address: yangqianqian1949@njmu.edu.cn.
  • DOI: 10.1016/j.biopha.2022.114087 PMID: 36481400

    摘要 Ai翻译

    <p> <strong class="sub-title"> Background and objective: </strong> Doxorubicin (DOX) is one of the most commonly used antineoplastic agents; however, its considerable nephrotoxicity restricts its clinical use. Kaempferol (KPF), a na... ...

    Copyright © Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Biomedicine & pharmacotherapy

    缩写:BIOMED PHARMACOTHER

    ISSN:0753-3322

    e-ISSN:1950-6007

    IF/分区:7.5/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Kaempferol attenuates doxorubicin-induced renal tubular injury by inhibiting ROS/ASK1-mediated activation of the MAPK signaling pathway